article thumbnail

Regional inequalities threatening Europe’s biosimilars market

European Pharmaceutical Review

The report noted that biosimilar adoption levels vary significantly across Europe because of differences in baseline use of biologics, biosimilar reimbursement, procurement, policies, and education, based on research published in a paper in the Journal of Market Access & Health Policy in 2017.

article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. Between 2013 and 2017, the price of a 50-tablet pack of prochlorperazine increased from £6.49 million to about £7.5 million, according to the CMA.

Pharma 57
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

Increased competition and evolving standard of care New competitors are entering the market at a rapid pace, and competition is intensifying. This competitive intensity tends to focus on smaller patient populations with multiple treatment options (1,2). Specific challenges facing the oncology field 1.

article thumbnail

470% price increases

World of DTC Marketing

For a patient taking 3 tablets daily, the annual net price of Imbruvica increased from $72,587 in 2013 to $115,533 in 2017 (the last year for which AbbVie provided the Committee data). AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. net revenue from Humira.

article thumbnail

Roche CEO Severin Schwan to stand down after 14 years

pharmaphorum

The appointment might raise some eyebrows given Roche’s need to drive pharma sales as it copes with the loss of patent protection on an earlier generation of antibody-based therapies – now being hit by biosimilar competition – but Schwan is confident Schinecker is the right man to lead the company forward.

Sales 105
article thumbnail

Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth

Pharmaceutical Technology

Upcoming biosimilar competition for Humira means AbbVie’s focus may turn to Rinvoq, approved in the US for atopic dermatitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis, and Skyrizi, approved in the US for psoriatic arthritis and plaque psoriasis. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%

Sales 108
article thumbnail

Newron says pivotal treatment-resistant schizophrenia trial is a go

pharmaphorum

Newron already markets Xadago (safinamide) as an add-on treatment for Parkinson’s disease, securing approval in 2017 after a marathon drug development effort that was also plagued by delays. ” The new data could accelerate partnering efforts of the drug this year.